Loading...
OTCM
NWBO
Market cap389mUSD
Jun 06, Last price  
0.27USD
1D
7.57%
1Q
7.57%
Jan 2017
-22.41%
IPO
-99.98%
Name

Northwest Biotherapeutics Inc

Chart & Performance

D1W1MN
P/E
—
P/S
281.65
EPS
—
Div Yield, %
—
Shrs. gr., 5y
17.10%
Rev. gr., 5y
-10.53%
Revenues
1m
-28.47%
124,000800,00010,00010,00010,00010,00010,000772,000809,0001,454,0001,739,000623,000336,000412,0002,410,0001,291,0001,005,0001,683,0001,932,0001,382,000
Net income
-85m
L+36.09%
-9,937,000-1,395,000-21,257,000-22,331,000-25,271,000-27,368,000-32,830,000-67,320,000-65,789,000-135,634,000-114,741,000-80,214,000-73,143,000-35,794,000-23,572,000-538,365,000179,126,000-136,848,000-62,599,000-85,192,000
CFO
-57m
L+6.30%
-4,184,000-6,930,000-14,601,000-15,587,000-4,677,000-6,376,000-14,707,000-22,754,000-37,800,000-54,576,000-78,608,000-55,652,000-36,495,000-34,586,000-31,859,000-32,093,000-38,299,000-52,775,000-53,637,000-57,017,000
Earnings
Aug 07, 2025

Profile

Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.
URL
https://nwbio.com/
IPO date
Dec 14, 2001
Employees
22
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,382
-28.47%
1,932
14.80%
1,683
67.46%
Cost of revenue
67,890
85,170
70,412
Unusual Expense (Income)
NOPBT
(66,508)
(83,238)
(68,729)
NOPBT Margin
Operating Taxes
31,816
Tax Rate
NOPAT
(66,508)
(83,238)
(100,545)
Net income
(85,192)
36.09%
(62,599)
-54.26%
(136,848)
-176.40%
Dividends
Dividend yield
Proceeds from repurchase of equity
14,217
15,047
39,291
BB yield
-4.17%
-1.92%
-4.93%
Debt
Debt current
34,706
21,108
15,892
Long-term debt
37,498
29,534
15,085
Deferred revenue
Other long-term liabilities
4,700
4,950
23,060
Net debt
70,029
48,516
23,933
Cash flow
Cash from operating activities
(57,017)
(53,637)
(52,775)
CAPEX
(3,437)
(2,902)
Cash from investing activities
(1,014)
(3,437)
(2,902)
Cash from financing activities
56,785
52,758
41,968
FCF
(55,895)
(165,781)
(108,499)
Balance
Cash
2,175
2,126
6,965
Long term investments
79
Excess cash
2,106
2,029
6,960
Stockholders' equity
(1,423,621)
(1,338,292)
(1,269,849)
Invested Capital
1,416,781
1,342,061
1,191,059
ROIC
ROCE
972.34%
87.23%
EV
Common stock shares outstanding
1,242,237
1,119,191
1,015,852
Price
0.27
-60.81%
0.70
-10.64%
0.78
12.07%
Market cap
341,305
-56.50%
784,553
-1.55%
796,936
12.96%
EV
426,841
851,787
843,929
EBITDA
(64,464)
(81,505)
(67,229)
EV/EBITDA
Interest
7,767
5,241
6,068
Interest/NOPBT